Hemostemix (CVE:HEM) Stock Price Up 25% – What’s Next?

Hemostemix Inc. ( CVE:HEM – Get Free Report ) was up 25% on Friday . The company traded as high as C$0.

36 and last traded at C$0.35. Approximately 1,444,856 shares were traded during trading, an increase of 111% from the average daily volume of 684,559 shares.



The stock had previously closed at C$0.28. Hemostemix Stock Performance The stock has a market capitalization of C$32.

67 million, a PE ratio of -18.75 and a beta of 0.20.

The business has a 50 day moving average of C$0.13 and a two-hundred day moving average of C$0.09.

About Hemostemix ( Get Free Report ) Hemostemix Inc, a clinical stage biotechnology company, develops, manufactures, and commercializes blood-derived stem cell therapies for medical conditions in Canada. Its lead product is ACP-01, an autologous cell therapy, which is in Phase II clinical trial for the treatment of vascular diseases, such as cardiovascular disease, peripheral arterial disease, angina pectoris, and ischemia. Read More Five stocks we like better than Hemostemix Market Cap Calculator: How to Calculate Market Cap Bloom Energy: Powering the Future With Decentralized Energy What Are Trending Stocks? Trending Stocks Explained Dividend Powerhouses: Blue-Chip Stocks Built for the Long Haul What is Short Interest? How to Use It Why Traders Are Buying the Dip on Johnson & Johnson Stock Receive News & Ratings for Hemostemix Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Hemostemix and related companies with MarketBeat.

com's FREE daily email newsletter ..